Catherine Skari
-
Mar- 2024 -22 March
-
22 March
-
22 March
-
17 MarchScientific Literature
Magnitude of Bone Disease in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia Patients
Introduction: β-Thalassemia is a common inherited disease in the northern part of Iraq. A considerable number of transfusion-dependent (TDT) and…
Read More » -
10 March
-
4 MarchScientific Literature
Alpha-Thalassemia: A Practical Overview
α-Thalassemia is an inherited blood disorder characterized by decreased synthesis of α-globin chains that results in an imbalance of α and β globin and…
Read More » -
4 MarchNews
EXCLUSIVE WEBINAR | Guidelines for the Management of a-Thalassaemia |14 March 2024
📌 Webinar Title: Guidelines for the Management of α-Thalassaemia 📌 Date & Time: Thursday, March 14, 2024, 13:00 Bangkok /…
Read More » -
3 MarchNews
SPOTLIGHT | RAIN Endorses the First International Guidelines for Pyruvate Kinase Deficiency
Pyruvate kinase deficiency (PKD) is the most common cause of chronic congenital non-spherocytic haemolytic anaemia, impacting between one in 100,000…
Read More » -
Feb- 2024 -28 FebruaryScientific Literature
The Italian Breakthrough in CRISPR trials for Rare Diseases: A focus on β-Thalassemia and Sickle Cell Disease Treatment
The development of gene therapy and the current advantageous method of clustered regularly interspaced short palindromic repeats (CRISPRs) has allowed…
Read More » -
28 FebruaryNews
REGULATORY NEWS | AstraZeneca’s Voydeya Recommended for PNH Treatment in EU
Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the…
Read More »
